BiOptic Inc.
BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications. It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits. BiOptic Inc.was fou… Read more
BiOptic Inc. (6850) - Total Assets
Latest total assets as of June 2025: NT$586.19 Million TWD
Based on the latest financial reports, BiOptic Inc. (6850) holds total assets worth NT$586.19 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BiOptic Inc. - Total Assets Trend (2020–2024)
This chart illustrates how BiOptic Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BiOptic Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
BiOptic Inc.'s total assets of NT$586.19 Million consist of 49.9% current assets and 50.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 16.5% |
| Accounts Receivable | NT$37.30 Million | 6.3% |
| Inventory | NT$155.24 Million | 26.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$15.37 Million | 2.6% |
| Goodwill | NT$27.55 Million | 4.6% |
Asset Composition Trend (2020–2024)
This chart illustrates how BiOptic Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BiOptic Inc.'s current assets represent 49.9% of total assets in 2024, a decrease from 54.1% in 2020.
- Cash Position: Cash and equivalents constituted 16.5% of total assets in 2024, down from 21.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 26.0% of total assets.
BiOptic Inc. Competitors by Total Assets
Key competitors of BiOptic Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BiOptic Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BiOptic Inc. generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, BiOptic Inc. generates $ 3.81 in net profit.
BiOptic Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.27 | 5.99 | 4.44 |
| Quick Ratio | 3.20 | 2.15 | 3.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$244.30 Million | NT$ 231.25 Million | NT$ 288.60 Million |
BiOptic Inc. - Advanced Valuation Insights
This section examines the relationship between BiOptic Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.8% |
| Total Assets | NT$596.41 Million |
| Market Capitalization | $12.60K USD |
Valuation Analysis
Below Book Valuation: The market values BiOptic Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: BiOptic Inc.'s assets decreased by 2.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BiOptic Inc. (2020–2024)
The table below shows the annual total assets of BiOptic Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$596.41 Million | -2.83% |
| 2023-12-31 | NT$613.77 Million | +17.71% |
| 2022-12-31 | NT$521.44 Million | +24.31% |
| 2021-12-31 | NT$419.48 Million | +44.22% |
| 2020-12-31 | NT$290.86 Million | -- |